1. Home
  2. BPYPO vs GNLX Comparison

BPYPO vs GNLX Comparison

Compare BPYPO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Property Partners L.P.

BPYPO

Brookfield Property Partners L.P.

N/A

Current Price

$14.56

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$4.36

Market Cap

202.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BPYPO
GNLX
Founded
N/A
2001
Country
Bermuda
United States
Employees
30200
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
202.4M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
BPYPO
GNLX
Price
$14.56
$4.36
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.75
AVG Volume (30 Days)
N/A
140.8K
Earning Date
N/A
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.99
52 Week High
N/A
$8.54

Technical Indicators

Market Signals
Indicator
BPYPO
GNLX
Relative Strength Index (RSI) 47.88 40.94
Support Level $14.40 $4.20
Resistance Level $14.85 $4.37
Average True Range (ATR) 0.19 0.25
MACD 0.03 0.06
Stochastic Oscillator 53.86 46.90

Price Performance

Historical Comparison
BPYPO
GNLX

About BPYPO Brookfield Property Partners L.P.

Brookfield Property Partners LP owns, operates, and invests in commercial properties in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Share on Social Networks: